Pfizer announced positive topline results from two pivotal Phase 3 studies showing LITFULO (ritlecitinib) significantly improved facial and total repigmentation compared to placebo at 52 weeks in patients with nonsegmental vitiligo. The studies represent the largest Phase 3 program to date for an oral systemic therapy in this indication.
Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.
Tech entrepreneur and anti-aging advocate Bryan Johnson announced he has created what he describes as a 'newborn' version of himself using stem cells, with the goal of growing replacement organs after being diagnosed with autoimmune gastritis. The controversial experiment represents his latest effort in his 'Don't Die' longevity campaign.
